PEPTIDESTAT
ApprovedWeight lossSubcutaneousEvidence 5/5

Dulaglutide

Also known as: Trulicity

Dulaglutide is a long-acting GLP-1 receptor agonist that stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite.

Read guideBuy / compare source
Dulaglutide
Drug class
GLP-1 receptor agonist (Fc-fusion peptide)
Primary targets
GLP-1 receptor
Dose reference
FDA label (not a recommendation): 0.75 mg, 1.5 mg, 3 mg or 4.5 mg subcutaneously once weekly
Half-life
Approximately 5 days
Developer / origin
Eli Lilly
Reference year
2014
Evidence score
5/5 - Strong
Evidence 5/5

Strong

Dulaglutide has robust, peer-reviewed primary evidence: the AWARD phase 3 program established dose-related glycemic efficacy, the REWIND randomized outcomes trial (9,901 participants, ~5.4 year median follow-up) demonstrated a reduction in major adverse cardiovascular events (HR 0.88), and an FDA label backs both diabetes and cardiovascular indications.

Approved medication with substantial human clinical evidence.

Evidence basis

  • REWIND double-blind randomized placebo-controlled cardiovascular outcomes trial in The Lancet (2019), n=9,901
  • AWARD-11 randomized controlled trial supporting expanded 3.0 mg and 4.5 mg doses in Diabetes Care (2021)
  • FDA Trulicity prescribing information and DailyMed label with approved indications and pharmacokinetics

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

Dulaglutide guides

Read the matching guide or adjacent research pages for more context.

Dulaglutide Peptide: Trulicity, AWARD and REWIND EvidenceDulaglutide is an FDA-approved once-weekly GLP-1 receptor agonist with strong type 2 diabetes and cardiovascular outcome evidence, plus a boxed thyroid warning.Every GLP-1 Drug Approved in 2026 (Plus the Pipeline)Seven GLP-1 receptor agonists carry FDA approval in 2026 across diabetes and weight-management labels, with a deep pipeline behind them — brand names, doses and approval years for each.Peptides for Weight Loss: GLP-1s, Tirzepatide, Retatrutide and What WorksA broad guide to weight-loss peptides, from approved GLP-1 and dual-incretin medicines to investigational retatrutide, cagrilintide and other research compounds.GLP-1 for Weight Loss: How Well They Work, and What They CostGLP-1 weight-loss drugs produce 8–21% average body-weight reduction in trials. The honest version weighs eligibility, results, cost, side effects, and the rebound after you stop.

Peptide calculators

Use calculators for concentration, unit conversion and repeated-dose accumulation math.

Peptide reconstitution calculatorCalculate concentration, draw volume and syringe units from vial strength and BAC water.Open toolPeptide accumulation calculatorModel repeated dosing schedules with half-life, interval, peak and trough estimates.Open toolPeptide unit converterConvert mg, mcg, optional IU and syringe units from one reconstituted vial setup.Open toolPeptide chemistry calculatorAnalyze sequence length, molecular weight, composition, charge, hydropathy and notation.Open tool

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Retatrutide

LY3437943

4/5
Weight lossInvestigational

Activates GLP-1, GIP and glucagon receptors simultaneously to suppress appetite and raise energy expenditure.

DetailsGuide

Tirzepatide

LY3298176, Mounjaro, Zepbound

5/5
Weight lossApproved

Activates GLP-1 and GIP receptors to improve glycemic control and reduce appetite + body weight.

DetailsGuide

Semaglutide

Ozempic, Wegovy, Rybelsus

5/5
Weight lossApproved

Mimics the incretin GLP-1, slowing gastric emptying and reducing appetite while improving insulin secretion.

DetailsGuide

Liraglutide

Victoza, Saxenda

5/5
Weight lossApproved

Daily GLP-1 analog. Reduces appetite and improves glycemic control via the same incretin pathway as semaglutide.

DetailsGuide

Category hub

Open the category page for the full comparison table and FAQ.

Weight Loss Peptides

Compare weight loss peptides including GLP-1, GIP, amylin and triple-agonist compounds by approval status, mechanism, half-life and evidence score.

Research & educational purposes only

The information on PeptideStat is for educational and research purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use. Always consult a qualified healthcare professional before making any health decisions. Articles may contain affiliate links — we may earn a commission at no extra cost to you.